Home CAS Center for Excellence


Members of CAS, CAE
National Outstanding Young Scientists Award
Principal Investigators
Address: 320 Yue Yang Road, Shanghai 200031, P.R. China
Tel: 86-21-54920000
Fax: 86-21-54921011
Email: sibcb@sibs.ac.cn
Website: www.sibcb.ac.cn
Principal Investigators
Ph.D., Professor
Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yue-yang Road, Shanghai 200031, China.
Email: hai@@sibcb.ac.cn

Research Interests
Improving the efficacy of anti-cancer therapy is a major challenge for healthcare and biomedical research. With the rapidly improving understanding of human cancer genome, significant opportunities lie in the rational design of personalized medicine that attacks specific weakness of individual cancer. In addition, advances in chemistry and screening technology also allow for the development of new and more effective anti-cancer drugs. Combining RNAi technology and mouse models of cancer, we plan to address these important questions, aiming at establishing principles and tools for improving cancer therapy.
Major research topics in my lab include:
1) Modeling recurrent cancer genotypes to explore the genotype-specific vulnerabilities of human cancer
2) Screening and development of new anti-cancer drugs using a functional genetic drug-characterization approach
3) Knowledge-based redesign and improvement of existing anti-cancer drugs

Selected Publications

  1. Liu C, Ding H, Li X, Pallasch CP, Hong L, Guo D, Chen Y, Wang D, Wang W, Wang Y*, Hemann MT*, Jiang H*. A DNA/HDAC dual-targeting drug with significantly enhanced anticancer potency. (2015) EMBO Molecular Medicine, 7(4):438-49 (*Corresponding author)
  2. Wang N, Ding H, Liu H, Li X, Wei L, Yu J, Liu M, Ying M, Gao W, Jiang H* , Wang Y. A novel recurrent CHEK2 Y390C mutation identified in high risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk. (2015) Oncogene, 34(40):5198-205 (*Corresponding author)
  3. Wu J#, Jiang H#, Luo S#, , Zhang M, Zhang Y, Sun F, Huang S and Li H. Caspase-mediated cleavage of C53/LZAP protein causes abnormal microtubule bundling and rupture of the nuclear envelope. (2013) Cell Res, 23(5):691-704. (#equal contribution)
  4. Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT. A mammalian functional-genetic approach to characterizing cancer therapeutics. (2011) Nat Chem Biol. 7(2):92-100.
  5. Reinhardt HC#, Jiang H#, Hemann MT and Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy. (2009) Cell Cycle 8(19) :3112-9. (#equal contribution)
  6. Jiang H#, Reinhardt HC#, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT. The combined status of ATM and p53 link tumor development with therapeutic response. (2009) Genes Dev. 23(16):1895-909. (#equal contribution)
  7. Jiang H#, Wu J#He C, Yang W, Li H. Tumor suppressor protein C53 antagonizes checkpoint kinases to promote cyclin-dependent kinase 1 activation. (2009) Cell Res. 19(4):458-68. (#equal contribution)
  8. Jiang H, Luo S, Li H. Cdk5 activator-binding protein C53 regulates apoptosis induced by genotoxic stress via modulating the G2/M DNA damage checkpoint. (2005) J Biol Chem. 280(21):20651-9

Education Background & Academic Experience
From 2011, Principle Investigator, Shanghai Institute of Biochemistry and Cell Biology (SIBCB), CAS, Shanghai, China.
2007-2011, Postdoctoral Associate, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
2000-2006, Doctor of Philosophy, the Integrated Graduate Program (Cancer / Cell Biology), Northwestern University, the Feinberg School of Medicine
1996-2000, Bachelor of Science, Department of Biotechnology, Peking University, Beijing, China

Research Team


Copyright © 2017-2020 Shanghai Institute of Biochemistry and Cell Biology, CAS. All rights reserved